Broad Range of Highly Potent Finished Dosage Form Contract Manufacturing Capabilities from Pfizer CentreSource Speaks to Outsourcing Demand

Article

A technical leader in solid dosage forms Pfizer CentreSource provides analytical, technical, regulatory, developmental, manufacturing and packaging support that spans the specialized realm of highly potent solid oral dose drug products.

Pfizer CentreSource (PCS), a leading global provider of active pharmaceutical ingredients, custom fermentation, and contract manufacturing services, reports robust demand for its suite of highly potent drug product development and manufacturing services. A technical leader in solid dosage forms, PCS’ analytical, technical, regulatory, developmental, manufacturing and packaging support spans the specialized realm of highly potent solid oral dose drug products.

According to PCS President Michael Kosko, the breadth and popularity of the company’s highly potent drug product services speaks to the global industry trend toward outsourcing and away from capital investment in high containment manufacturing.

“We’re seeing strong outsourcing demand across the specialized realm of highly potent solid oral dosage forms, from development services through clinical to commercial supply. There’s clearly a need for the collaborative, flexible and expert highly potent drug product services we provide,” he commented.

Part of Pfizer Global Supply (PGS), one of the world's leading supply organizations and an integral part of Pfizer Inc, PCS customers benefit from Pfizer’s analytical, regulatory and quality expertise, state-of-the-art high containment facilities and specialized technologies, including:

  • Sieving/Milling/Blending
  • Dry Granulation
  • High Shear Wet Granulation
  • Core Compression
  • Aqueous Film Coating
  • Encapsulation
  • Blister Packaging
  • Bottle Packaging
  • Carding/Wallet Packaging
Recent Videos
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content